The regulatory effects of propofol on cell proliferation, apoptosis, invasion and migration of human glioma cell line U251
ZHAO Hua-yu, HUO Shu-ping, LIU Yan-hui, KANG Shu-feng
Chinese Journal of Clinical Anatomy ›› 2018, Vol. 36 ›› Issue (6) : 626-631.
The regulatory effects of propofol on cell proliferation, apoptosis, invasion and migration of human glioma cell line U251
Objective To investigate the effects and mechanism of propofol on cell proliferation, apoptosis, invasion and migration of human glioma cell line U251. Methods Cells were divided into Propofol (1 M), Propofol (2 M) and Propofol (5 M) group and treated with propofol bisides U251 group. Cell proliferation was determined by CCK8 assay, flow cytometry was performed for cell apoptosis. The invasion and migration abilities of U251 cell were determined by Transwell and wound healing assays. The expressions of Ki67, Caspase-3, vascular endothelial growth factor (VEGF), phosphoinositide 3-kinase (PI3K), Akt, p-PI3K and p-Akt were measured by western blot. Results Compared with U251 group, the cell growth rate was decreased and cell apoptosis rate was increased in Propofol (1, 2, 5 M) groups. Meanwhile, the invasion cells in the propofol (1, 2, 5 M) groups were decreased compared with the U251 group, and wound closure rate was also down-regulated in the propofol (2, 5 M) groups. In addition, propofol inhibited the expressions of Ki67 and VEGF (proliferation- and migration-related proteins) and induced expression of apoptosis-related protein Caspase-3. Propofol also decreased the ratio of p-PI3K/PI3K and p-Akt/Akt significantly. Conclusions Propofol reduces the abilities of cell proliferation, invasion and migration of glioma cell line U251 and induces cell apoptosis, the mechanism of which may be related to inhibition of the activation of PI3K/Akt signaling pathway
Propofol; Glioma; Proliferation; Apoptosis / Invasion; Migration
[1] Popova SN, Bergqvist M, Dimberg A, et al. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry[J]. Histopathology, 2014, 64(3): 365-379.
[2] Xu J, Xu W, Zhu J. Propofol suppresses proliferation and invasion of glioma cells by upregulating microRNA-218 expression[J]. Mol Med Rep, 2015, 12(4): 4815- 4820.
[3] Shi R , Wang PY, Li XY, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients[J]. Oncotarget, 2015, 6(29): 26971-26981.
[4] Helseth R, Helseth E, Johannesen TB, et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme[J]. Acta Neurol Scand, 2010,122(3): 159-167.
[5] Chen X, Lu P, Chen L, et al. Perioperative propofol-paravertebral anesthesia decreases the metastasis and progression of breast cancer[J]. Tumor Biol, 2015, 36(11): 8259-8266.
[6] Wang ZT, Gong HY, Zheng F, et al. Propofol suppresses proliferation and invasion of gastric cancer cells via downregulation of microRNA-221 expression[J]. Genet Mol Res, 2015, 14(3): 8117-8124.
[7] Huang H, Benzonana LL, Zhao H, et al. Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination[J]. Br J Cancer, 2014, 111(7): 1338-1349.
[8] Wang P, Chen J, Mu LH, et al. Propofol inhibits invasion and enhances paclitaxel- induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug[J]. Eur Rev Med Pharmacol Sci, 2013, 17(13): 1722-1729.
[9] Wang XY, Li YL, Wang HY, et al. Propofol inhibits invasion and proliferation of C6 glioma cells by regulating the Ca2+ permeable AMPA receptor-system Xc-, pathway[J]. Toxicol In Vitro, 2017, 44: 57-65.
[10]Peng B, Li D, Qin M, et al. MicroRNA218 inhibits glioma migration and invasion via inhibiting glioma-associated oncogene homolog 1 expression at N terminus[J]. Tumor Biol, 2014, 35(4): 3831-3837.
[11]Zhu M, Chen L, Zhao P, et al. Store-operated Ca2+ entry regulates glioma cell migration and invasion via modulation of Pyk2 phosphorylation[J]. J Exp Clin Cancer Res, 2014, 33(1): 98-109.
[12]Horowitz M, Neeman E, Sharon E, et al. Exploiting the critical perioperative period to improve long-term cancer outcomes[J]. Nat Rev Clin Oncol, 2015, 12(4): 213-226.
[13]Priebe HJ. Aneurysmal subarachnoid haemorrhage and the anaesthetist[J]. Br J Anaesth, 2007, 99(1): 102-118.
[14]Su Z, Hou XK, Wen QP. Propofol induces apoptosis of epithelial ovarian cancer cells by upregulation of microRNA let-7i expression[J]. Eur J Gynaecol Oncol， 2014, 35(6): 688-691.
[15] Li LT, Jiang G, Chen Q, et al. Ki67 is a promising molecular target in the diagnosis of cancer (review)[J]. Mol Med Rep, 2015, 11(3): 1566-1572.
[16]Patel PB, Thakkar VR. L-carvone induces p53, caspase 3 mediated apoptosis and inhibits the migration of breast cancer cell lines[J]. Nutri Cancer, 2014, 66(3): 453-462.
[17] Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature[J]. Eur Urol, 2015, 67(5): 852-863.
[18]Wu KC, Yang ST, Hsia TC, et al. Suppression of cell invasion and migration by propofol are involved in down-regulating matrix metalloproteinase-2 and p38 MAPK signaling in A549 human lung adenocarcinoma epithelial cells[J]. Anticancer Res, 2012, 32(11): 4833-4842.
[19]Bai JJ, Lin CS, Ye HJ, et al. Propofol suppresses migration and invasion of breast cancer MDA-MB-231 cells by down-regulating H19[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2016, 36(9):1255-1259.
[20]Enlund M, Berglund A, Andreasson K, et al. The choice of anaesthetic-sevoflurane or propofol-and outcome from cancer surgery: A retrospective analysis[J]. Ups J Med Sci, 2014, 119(3): 251-261.
[21] Li J, Li L, Li Z, et al. The role of miR-205 in the VEGF-mediated promotion of human ovarian cancer cell invasion[J]. Gynecol Oncol, 2015, 137(1): 125-133.
[22] Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance[J]. Asian J Androl, 2014, 16(3): 378-386.
[23] Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J]. Pharmacol Ther, 2014, 142(2): 164-175.
[24]Deng F, Ouyang M, Wang X, et al. Differential role of intravenous anesthetics in colorectal cancer progression: implications for clinical application[J]. Oncotarget, 2016, 7(47): 77087-77095.
/
| 〈 |
|
〉 |
